Ventyx Biosciences, Inc.

NasdaqGS:VTYX Stock Report

Market Cap: US$130.8m

Ventyx Biosciences Valuation

Is VTYX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VTYX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VTYX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VTYX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VTYX?

Key metric: As VTYX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for VTYX. This is calculated by dividing VTYX's market cap by their current book value.
What is VTYX's PB Ratio?
PB Ratio0.5x
BookUS$278.77m
Market CapUS$130.81m

Price to Book Ratio vs Peers

How does VTYX's PB Ratio compare to its peers?

The above table shows the PB ratio for VTYX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average7.8x
MIST Milestone Pharmaceuticals
5.1x63.6%US$121.9m
PROC Procaps Group
3.6xn/aUS$103.8m
NGM NGM Biopharmaceuticals
0.9x14.7%US$128.5m
RANI Rani Therapeutics Holdings
21.5x25.2%US$67.2m
VTYX Ventyx Biosciences
0.5x5.8%US$130.8m

Price-To-Book vs Peers: VTYX is good value based on its Price-To-Book Ratio (0.5x) compared to the peer average (7.8x).

Price to Book Ratio vs Industry

How does VTYX's PB Ratio compare vs other companies in the US Pharmaceuticals Industry?

23 CompaniesPrice / BookEstimated GrowthMarket Cap
SHWZ Medicine Man Technologies
0.09xn/aUS$8.82m
TNFA TNF Pharmaceuticals
0.2xn/aUS$3.69m
UPC Universe Pharmaceuticals
0.1xn/aUS$3.04m
CYTO Altamira Therapeutics
0.2x-5.9%US$1.44m
VTYX 0.5xIndustry Avg. 1.7xNo. of Companies28PB01.22.43.64.86+
23 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: VTYX is good value based on its Price-To-Book Ratio (0.5x) compared to the US Pharmaceuticals industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is VTYX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VTYX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate VTYX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VTYX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.06
US$10.50
+409.7%
54.1%US$21.00US$2.00n/a8
Nov ’25US$2.15
US$10.63
+394.2%
53.2%US$21.00US$2.00n/a8
Oct ’25US$2.08
US$10.63
+410.8%
53.2%US$21.00US$2.00n/a8
Sep ’25US$2.23
US$10.63
+376.5%
53.2%US$21.00US$2.00n/a8
Aug ’25US$2.24
US$10.80
+382.1%
48.8%US$21.00US$5.00n/a10
Jul ’25US$2.26
US$10.80
+377.9%
48.8%US$21.00US$5.00n/a10
Jun ’25US$4.78
US$10.70
+123.8%
51.5%US$21.00US$5.00n/a10
May ’25US$4.68
US$10.80
+130.8%
50.3%US$21.00US$5.00n/a10
Apr ’25US$5.59
US$10.80
+93.2%
50.3%US$21.00US$5.00n/a10
Mar ’25US$8.50
US$9.67
+13.7%
61.7%US$21.00US$5.00n/a9
Feb ’25US$2.24
US$8.88
+296.2%
76.3%US$21.00US$3.00n/a8
Jan ’25US$2.47
US$8.88
+259.3%
76.3%US$21.00US$3.00n/a8
Dec ’24US$2.20
US$9.50
+331.8%
67.6%US$21.00US$5.00n/a8
Nov ’24US$14.44
US$54.20
+275.3%
16.6%US$77.00US$43.00US$2.1510
Oct ’24US$34.73
US$57.10
+64.4%
14.5%US$77.00US$46.00US$2.0810
Sep ’24US$33.75
US$56.75
+68.1%
14.3%US$77.00US$46.00US$2.2312
Aug ’24US$37.19
US$57.58
+54.8%
14.1%US$77.00US$45.00US$2.2412
Jul ’24US$32.80
US$57.58
+75.6%
14.1%US$77.00US$45.00US$2.2612
Jun ’24US$33.98
US$57.58
+69.5%
14.1%US$77.00US$45.00US$4.7812
May ’24US$39.15
US$57.25
+46.2%
14.6%US$77.00US$45.00US$4.6812
Apr ’24US$33.50
US$57.25
+70.9%
14.6%US$77.00US$45.00US$5.5912
Mar ’24US$44.37
US$55.00
+24.0%
10.9%US$65.00US$45.00US$8.5011
Feb ’24US$40.85
US$55.00
+34.6%
10.9%US$65.00US$45.00US$2.2411
Jan ’24US$32.79
US$51.45
+56.9%
13.8%US$63.00US$35.00US$2.4711
Dec ’23US$29.54
US$51.60
+74.7%
14.4%US$63.00US$35.00US$2.2010
Nov ’23US$33.65
US$52.56
+56.2%
16.9%US$65.00US$35.00US$14.449

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$204.02

7D

6.8%

1Y

-3.2%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$58.64

7D

6.1%

1Y

14.8%